Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Valeant Pharmaceuticals (VRX) PT Lifted to $271 at Cantor Fitzgerald
April 30, 2015 6:51 AM EDTCantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) price target of $271.00 (from $222.00) amid "strong" Q1 results.
Koffler commented, "Valeant reported revenues of $2.19B (+16% Y/Y) and adjusted non-GAAP EPS of $2.36 in 1Q:15 vs. guidance of 10-15% organic revenue growth and >$2.30 and FactSet consensus of... More
Valeant Pharmaceuticals (VRX) PT Lifted to $250 at Guggenheim Post Q1
April 29, 2015 10:16 AM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) to $250.00 (from $210.00) following Q1 beat and better-than-expected 2016 outlook.
Chen commented, "The 1Q15 beat and better-than-expected outlook for '16+ support our positive thesis for... More
Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
April 29, 2015 6:16 AM EDTValeant Pharma (NYSE: VRX) reported Q1 EPS of $2.36, versus $1.76 reported last year. Revenue for the quarter came in at $2.2 billion, versus $1.89 billion reported last year.
Valeant also announced that Howard B. Schiller has advised the Company of his decision to step down as Chief Financial Officer once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds. With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant Board and, with the Board's continued... More
